SEC Form 4 · accession 0001209191-19-004782

NovoCure Ltd · NVCR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jan 18, 2019

Accepted (ET)

Jan 22, 2019 · 5:13 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001645113

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Ordinary Shares^F1	Jan 18, 2019	M	46,863	$3.44	A	218,027	D
Ordinary Shares^F2	Jan 18, 2019	S	33,219	$45.804	D	184,808	D
Ordinary Shares^F3	Jan 18, 2019	S	13,644	$46.159	D	171,164	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Options to Buy Ordinary Shares^F4	$3.44	Jan 18, 2019	M	46,863	D	—	Dec 13, 2021	Ordinary Shares	46,863	0	D

F1These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger.
F2On January 18, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 33,219 shares in multiple trades at prices ranging from $45.06 to $46.05. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F3On January 18, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 13,644 shares in multiple trades at prices ranging from $46.06 to $46.44. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F4Fully vested and currently exercisable as of the date hereof.